Do analysts rate NAII or FLNA?

Cassava Sciences has a consensus price target of $5.00, suggesting a potential upside of 253.36%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Cassava Sciences is more favorable than Natural Alternatives International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natural Alternatives International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor NAII or FLNA?

In the previous week, Natural Alternatives International and Natural Alternatives International both had 1 articles in the media. Cassava Sciences' average media sentiment score of 1.04 beat Natural Alternatives International's score of 0.58 indicating that Cassava Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natural Alternatives International 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cassava Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NAII or IZTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natural Alternatives International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, NAII or IZTC?

Invizyne Technologies has lower revenue, but higher earnings than Natural Alternatives International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natural Alternatives International $129.86M 0.12 -$13.57M -$2.39 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Do analysts prefer NAII or ENTX?

Entera Bio has a consensus target price of $9.00, indicating a potential upside of 634.69%. Given Entera Bio's stronger consensus rating and higher probable upside, analysts plainly believe Entera Bio is more favorable than Natural Alternatives International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natural Alternatives International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Entera Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor NAII or ENTX?

In the previous week, Entera Bio had 1 more articles in the media than Natural Alternatives International. MarketBeat recorded 2 mentions for Entera Bio and 1 mentions for Natural Alternatives International. Natural Alternatives International's average media sentiment score of 0.58 beat Entera Bio's score of 0.47 indicating that Natural Alternatives International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natural Alternatives International 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entera Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate NAII or CING?

Cingulate has a consensus price target of $28.33, indicating a potential upside of 492.87%. Given Cingulate's stronger consensus rating and higher possible upside, analysts plainly believe Cingulate is more favorable than Natural Alternatives International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natural Alternatives International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cingulate 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media prefer NAII or CING?

In the previous week, Cingulate had 8 more articles in the media than Natural Alternatives International. MarketBeat recorded 9 mentions for Cingulate and 1 mentions for Natural Alternatives International. Cingulate's average media sentiment score of 0.68 beat Natural Alternatives International's score of 0.58 indicating that Cingulate is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natural Alternatives International 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cingulate 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend NAII or DWTX?

Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 612.59%. Given Dogwood Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than Natural Alternatives International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natural Alternatives International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Natural Alternatives International (NAII) Competitors

$2.56 +0.05 (+1.79%)

As of 02:29 PM Eastern

Compare

NAII vs. FLNA, IZTC, ENTX, CING, and DWTX

Should you buy Natural Alternatives International stock or one of its competitors? MarketBeat compares Natural Alternatives International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Natural Alternatives International include Cassava Sciences (FLNA), Invizyne Technologies (IZTC), Entera Bio (ENTX), Cingulate (CING), and Dogwood Therapeutics (DWTX). These companies are all part of the "pharmaceutical products" industry.

How does Natural Alternatives International compare to Cassava Sciences?

Natural Alternatives International (NASDAQ:NAII) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

In the previous week, Natural Alternatives International and Natural Alternatives International both had 1 articles in the media. Cassava Sciences' average media sentiment score of 1.04 beat Natural Alternatives International's score of 0.58 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natural Alternatives International	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cassava Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Natural Alternatives International has higher revenue and earnings than Cassava Sciences. Natural Alternatives International is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natural Alternatives International	$129.86M	0.12	-$13.57M	-$2.39	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

32.4% of Natural Alternatives International shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 20.8% of Natural Alternatives International shares are held by company insiders. Comparatively, 4.6% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cassava Sciences has a consensus price target of $5.00, suggesting a potential upside of 253.36%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Cassava Sciences is more favorable than Natural Alternatives International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Natural Alternatives International has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.71, suggesting that its share price is 171% less volatile than the broader market.

Cassava Sciences has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Natural Alternatives International's return on equity of -12.21% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natural Alternatives International	-10.13%	-12.21%	-5.30%
Cassava Sciences	N/A	-53.90%	-34.20%

Summary

Cassava Sciences beats Natural Alternatives International on 8 of the 14 factors compared between the two stocks.

How does Natural Alternatives International compare to Invizyne Technologies?

Natural Alternatives International (NASDAQ:NAII) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

In the previous week, Natural Alternatives International had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 1 mentions for Natural Alternatives International and 0 mentions for Invizyne Technologies. Invizyne Technologies' average media sentiment score of 0.75 beat Natural Alternatives International's score of 0.58 indicating that Invizyne Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Natural Alternatives International	Positive
Invizyne Technologies	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Invizyne Technologies has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Invizyne Technologies' return on equity of 0.00% beat Natural Alternatives International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natural Alternatives International	-10.13%	-12.21%	-5.30%
Invizyne Technologies	N/A	N/A	N/A

32.4% of Natural Alternatives International shares are held by institutional investors. 20.8% of Natural Alternatives International shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Invizyne Technologies has lower revenue, but higher earnings than Natural Alternatives International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natural Alternatives International	$129.86M	0.12	-$13.57M	-$2.39	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Summary

Natural Alternatives International beats Invizyne Technologies on 5 of the 9 factors compared between the two stocks.

How does Natural Alternatives International compare to Entera Bio?

Natural Alternatives International (NASDAQ:NAII) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

32.4% of Natural Alternatives International shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 20.8% of Natural Alternatives International shares are owned by company insiders. Comparatively, 10.4% of Entera Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Entera Bio has lower revenue, but higher earnings than Natural Alternatives International. Entera Bio is trading at a lower price-to-earnings ratio than Natural Alternatives International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natural Alternatives International	$129.86M	0.12	-$13.57M	-$2.39	N/A
Entera Bio	$40K	1,507.36	-$11.44M	-$0.27	N/A

Entera Bio has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Natural Alternatives International's return on equity of -12.21% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natural Alternatives International	-10.13%	-12.21%	-5.30%
Entera Bio	N/A	-83.31%	-70.83%

Natural Alternatives International has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Entera Bio has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market.

Entera Bio has a consensus target price of $9.00, indicating a potential upside of 634.69%. Given Entera Bio's stronger consensus rating and higher probable upside, analysts plainly believe Entera Bio is more favorable than Natural Alternatives International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Entera Bio had 1 more articles in the media than Natural Alternatives International. MarketBeat recorded 2 mentions for Entera Bio and 1 mentions for Natural Alternatives International. Natural Alternatives International's average media sentiment score of 0.58 beat Entera Bio's score of 0.47 indicating that Natural Alternatives International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natural Alternatives International	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entera Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Entera Bio beats Natural Alternatives International on 9 of the 16 factors compared between the two stocks.

How does Natural Alternatives International compare to Cingulate?

Natural Alternatives International (NASDAQ:NAII) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Natural Alternatives International has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.85, indicating that its stock price is 185% less volatile than the broader market.

Cingulate has a consensus price target of $28.33, indicating a potential upside of 492.87%. Given Cingulate's stronger consensus rating and higher possible upside, analysts plainly believe Cingulate is more favorable than Natural Alternatives International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

32.4% of Natural Alternatives International shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 20.8% of Natural Alternatives International shares are held by insiders. Comparatively, 4.3% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cingulate has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Natural Alternatives International's return on equity of -12.21% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natural Alternatives International	-10.13%	-12.21%	-5.30%
Cingulate	N/A	-365.15%	-158.55%

In the previous week, Cingulate had 8 more articles in the media than Natural Alternatives International. MarketBeat recorded 9 mentions for Cingulate and 1 mentions for Natural Alternatives International. Cingulate's average media sentiment score of 0.68 beat Natural Alternatives International's score of 0.58 indicating that Cingulate is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natural Alternatives International	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cingulate	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Natural Alternatives International has higher revenue and earnings than Cingulate. Cingulate is trading at a lower price-to-earnings ratio than Natural Alternatives International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natural Alternatives International	$129.86M	0.12	-$13.57M	-$2.39	N/A
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A

Summary

Natural Alternatives International beats Cingulate on 8 of the 15 factors compared between the two stocks.

How does Natural Alternatives International compare to Dogwood Therapeutics?

Natural Alternatives International (NASDAQ:NAII) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Natural Alternatives International has higher revenue and earnings than Dogwood Therapeutics. Natural Alternatives International is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natural Alternatives International	$129.86M	0.12	-$13.57M	-$2.39	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Dogwood Therapeutics has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Natural Alternatives International's return on equity of -12.21% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natural Alternatives International	-10.13%	-12.21%	-5.30%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

Natural Alternatives International has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market.

Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 612.59%. Given Dogwood Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than Natural Alternatives International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

32.4% of Natural Alternatives International shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 20.8% of Natural Alternatives International shares are held by company insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Natural Alternatives International had 1 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 1 mentions for Natural Alternatives International and 0 mentions for Dogwood Therapeutics. Dogwood Therapeutics' average media sentiment score of 1.89 beat Natural Alternatives International's score of 0.58 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Natural Alternatives International	Positive
Dogwood Therapeutics	Very Positive

Summary

Natural Alternatives International beats Dogwood Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Natural Alternatives International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAII vs. The Competition

Export

Metric	Natural Alternatives International	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.05M	$2.96B	$6.42B	$12.48B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-1.07	18.04	23.85	24.39
Price / Sales	0.12	296.06	520.29	116.29
Price / Cash	N/A	55.72	41.27	57.13
Price / Book	0.23	3.92	10.04	6.74
Net Income	-$13.57M	$75.85M	$3.56B	$337.03M
7 Day Performance	-3.22%	-2.17%	-1.09%	0.13%
1 Month Performance	N/A	N/A	N/A	-1.67%
1 Year Performance	-25.29%	22.51%	28.56%	34.29%

Natural Alternatives International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAII Natural Alternatives International	1.5957 of 5 stars	$2.56 +1.8%	N/A	-24.9%	$16.05M	$129.86M	N/A	290	Gap Up
FLNA Cassava Sciences	2.1092 of 5 stars	$1.41 +7.6%	$5.00 +254.6%	-37.0%	$63.28M	N/A	N/A	20	Positive News
IZTC Invizyne Technologies	N/A	$9.92 +5.5%	N/A	-29.6%	$62.02M	N/A	N/A	29	Gap Up
ENTX Entera Bio	3.4598 of 5 stars	$1.21 -2.4%	$9.00 +643.8%	-41.2%	$61.04M	N/A	N/A	20
CING Cingulate	3.0893 of 5 stars	$4.78 +6.9%	$28.33 +492.7%	+22.6%	$60.21M	N/A	N/A	20	News Coverage Options Volume Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAII) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Natural Alternatives International (NAII) Competitors

NAII vs. FLNA, IZTC, ENTX, CING, and DWTX

How does Natural Alternatives International compare to Cassava Sciences?

Summary

How does Natural Alternatives International compare to Invizyne Technologies?

Summary

How does Natural Alternatives International compare to Entera Bio?

Summary

How does Natural Alternatives International compare to Cingulate?

Summary

How does Natural Alternatives International compare to Dogwood Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAII vs. The Competition

Natural Alternatives International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Natural Alternatives International (NAII) Competitors

NAII vs. FLNA, IZTC, ENTX, CING, and DWTX

How does Natural Alternatives International compare to Cassava Sciences?

Does the media favor NAII or FLNA?

Which has preferable valuation & earnings, NAII or FLNA?

Do insiders and institutionals have more ownership in NAII or FLNA?

Do analysts rate NAII or FLNA?

Which has more risk & volatility, NAII or FLNA?

Is NAII or FLNA more profitable?

Summary

How does Natural Alternatives International compare to Invizyne Technologies?

Does the media favor NAII or IZTC?

Do analysts rate NAII or IZTC?

Is NAII or IZTC more profitable?

Do institutionals & insiders have more ownership in NAII or IZTC?

Which has stronger earnings and valuation, NAII or IZTC?

Summary

How does Natural Alternatives International compare to Entera Bio?

Do insiders and institutionals hold more shares of NAII or ENTX?

Which has better valuation and earnings, NAII or ENTX?

Is NAII or ENTX more profitable?

Which has more volatility & risk, NAII or ENTX?

Do analysts prefer NAII or ENTX?

Does the media favor NAII or ENTX?

Summary

How does Natural Alternatives International compare to Cingulate?

Which has more volatility & risk, NAII or CING?

Do analysts rate NAII or CING?

Do insiders & institutionals hold more shares of NAII or CING?

Is NAII or CING more profitable?

Does the media prefer NAII or CING?

Which has better earnings and valuation, NAII or CING?

Summary

How does Natural Alternatives International compare to Dogwood Therapeutics?

Which has higher valuation and earnings, NAII or DWTX?

Is NAII or DWTX more profitable?

Which has more risk and volatility, NAII or DWTX?

Do analysts recommend NAII or DWTX?

Do institutionals and insiders hold more shares of NAII or DWTX?

Does the media favor NAII or DWTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAII vs. The Competition

Natural Alternatives International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools